Every year in the US alone, 2 million people report to the emergency room with stroke-like symptoms. About 800,000 of them have actually had a stroke. The identification of the cause of these strokes is a challenge—one that Jeff June took on when he founded Ischemia Care.
“In 40% of cases, the cause of stroke is never determined,” said June. This can impair a physician’s ability to prescribe proper treatment. “We work with leading clinicians and stroke centers to provide them with better tools to identify the cause of stroke and help prevent secondary recurrence.”
Ischemia Care is a molecular diagnostics company that commercializes blood tests for causes of stroke. Not only do Ischemia Care’s tests help improve patient outcomes, they can also significantly reduce hospital costs.
Annually, about $65 billion is spent triaging, identifying the cause of, and treating strokes in the US. June believes his company can significantly reduce that while improving the quality of patient care.
June and his team used the Applied Biosystems GeneChip Human Transcriptome Array 2.0 to generate gene expression and signature data for analysis prior to commercializing their first test, called the ISCDx test. Next, they plan to utilize Applied Biosystems qPCR solutions to achieve scalability.
“[The qPCR solutions] will help us increase throughput in the laboratory and reduce turnaround times,” said June.
In the future, June says that Ischemia Care will embark on a biomarker discovery journey and develop tests that could help clinicians determine whether or not a stroke has occurred, as well as the optimal form of intervention.